-
1
-
-
84865082196
-
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia
-
Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012;30(23):2820-2822.
-
(2012)
J Clin Oncol
, vol.30
, Issue.23
, pp. 2820-2822
-
-
Cheson, B.D.1
Byrd, J.C.2
Rai, K.R.3
-
2
-
-
84879779196
-
Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes [letter]
-
Hallek M, Cheson BD, Catovsky D, et al. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes [letter]. Blood. 2012;119(23): 5348.
-
(2012)
Blood
, vol.119
, Issue.23
, pp. 5348
-
-
Hallek, M.1
Cheson, B.D.2
Catovsky, D.3
-
3
-
-
40749132494
-
Chronic lymphocytic leukaemia
-
DOI 10.1016/S0140-6736(08)60456-0, PII S0140673608604560
-
Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017-1029. (Pubitemid 351389535)
-
(2008)
The Lancet
, vol.371
, Issue.9617
, pp. 1017-1029
-
-
Dighiero, G.1
Hamblin, T.2
-
4
-
-
77957664665
-
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial
-
Hallek M, Fischer K, Fingerle-Rowson G, et al.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
-
(2010)
Lancet
, vol.376
, Issue.9747
, pp. 1164-1174
-
-
Hallek, M.1
Fischer, K.2
Fingerle-Rowson, G.3
-
5
-
-
79954435811
-
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712
-
Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349-1355.
-
(2011)
J Clin Oncol
, vol.29
, Issue.10
, pp. 1349-1355
-
-
Woyach, J.A.1
Ruppert, A.S.2
Heerema, N.A.3
-
6
-
-
80053366228
-
Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: Long-term follow-up of US Intergroup Study E2997
-
Smith MR, Neuberg D, Flinn IW, et al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011;118(13):3525-3527.
-
(2011)
Blood
, vol.118
, Issue.13
, pp. 3525-3527
-
-
Smith, M.R.1
Neuberg, D.2
Flinn, I.W.3
-
7
-
-
33746257209
-
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
-
DOI 10.1038/nrg1879, PII NRG1879
-
Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-619. (Pubitemid 44100518)
-
(2006)
Nature Reviews Genetics
, vol.7
, Issue.8
, pp. 606-619
-
-
Engelman, J.A.1
Luo, J.2
Cantley, L.C.3
-
8
-
-
0038549067
-
PI3K in lymphocyte development, differentiation and activation
-
Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317-330. (Pubitemid 37328684)
-
(2003)
Nature Reviews Immunology
, vol.3
, Issue.4
, pp. 317-330
-
-
Okkenhaug, K.1
Vanhaesebroeck, B.2
-
9
-
-
77957201023
-
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
-
Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010; 116(12):2078-2088.
-
(2010)
Blood
, vol.116
, Issue.12
, pp. 2078-2088
-
-
Herman, S.E.1
Gordon, A.L.2
Wagner, A.J.3
-
10
-
-
78751553221
-
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
-
Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011; 117(2):591-594.
-
(2011)
Blood
, vol.117
, Issue.2
, pp. 591-594
-
-
Lannutti, B.J.1
Meadows, S.A.2
Herman, S.E.3
-
11
-
-
4344664011
-
A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cells
-
DOI 10.1038/sj.leu.2403398
-
Cuní S, Pérez-Aciego P, Pérez-Chacón G, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004; 18(8):1391-1400. (Pubitemid 39136749)
-
(2004)
Leukemia
, vol.18
, Issue.8
, pp. 1391-1400
-
-
Cuni, S.1
Perez-Aciego, P.2
Perez-Chacon, G.3
Vargas, J.A.4
Sanchez, A.5
Martin-Saavedra, F.M.6
Ballester, S.7
Garcia-Marco, J.8
Jorda, J.9
Durantez, A.10
-
12
-
-
80053345977
-
The phosphoinositide 39-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
-
Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 39-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603- 3612.
-
(2011)
Blood
, vol.118
, Issue.13
, pp. 3603-3612
-
-
Hoellenriegel, J.1
Meadows, S.A.2
Sivina, M.3
-
13
-
-
84868013848
-
Decreased mitochondrial apoptotic priming underlies stromamediated treatment resistance in chronic lymphocytic leukemia
-
Davids MS, Deng J, Wiestner A, et al. Decreased mitochondrial apoptotic priming underlies stromamediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012;12017 3501-3509.
-
(2012)
Blood
, vol.120
, Issue.17
, pp. 3501-3509
-
-
Davids, M.S.1
Deng, J.2
Wiestner, A.3
-
14
-
-
84859792782
-
Clinical pharmacokinetics of CAL-101, a p110{delta} isoform-selective PI3K inhibitor, following singleand multiple-dose administration in healthy volunteers and patients with hematological malignancies
-
Webb HK, Chen H, Yu AS, et al. Clinical pharmacokinetics of CAL-101, a p110{delta} isoform-selective PI3K inhibitor, following singleand multiple-dose administration in healthy volunteers and patients with hematological malignancies. ASH Annual Meeting Abstracts. 2010;116(21):1774.
-
(2010)
ASH Annual Meeting Abstracts
, vol.116
, Issue.21
, pp. 1774
-
-
Webb, H.K.1
Chen, H.2
Yu, A.S.3
-
15
-
-
45149100665
-
International workshop on chronic lymphocytic leukemia guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines
-
Hallek M, Cheson BD, Catovsky D, et al.; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
-
(2008)
Blood
, vol.111
, Issue.12
, pp. 5446-5456
-
-
Hallek, M.1
Cheson, B.D.2
Catovsky, D.3
-
16
-
-
77949881462
-
The PI3K pathway as drug target in human cancer
-
Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075-1083.
-
(2010)
J Clin Oncol
, vol.28
, Issue.6
, pp. 1075-1083
-
-
Courtney, K.D.1
Corcoran, R.B.2
Engelman, J.A.3
-
17
-
-
84865074467
-
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway
-
Busaidy NL, Farooki A, Dowlati A, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 2012;30(23):2919-2928.
-
(2012)
J Clin Oncol
, vol.30
, Issue.23
, pp. 2919-2928
-
-
Busaidy, N.L.1
Farooki, A.2
Dowlati, A.3
-
18
-
-
0036534380
-
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: Implications for clinical trials in this patient population
-
DOI 10.1002/cncr.10437
-
Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002;94(7):2033-2039. (Pubitemid 34270057)
-
(2002)
Cancer
, vol.94
, Issue.7
, pp. 2033-2039
-
-
Perkins, J.G.1
Flynn, J.M.2
Howard, R.S.3
Byrd, J.C.4
-
19
-
-
84886313545
-
Final results of a phase i study of idelalisib, a selective inhibitor of PI3Kd, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)
-
Benson DM, Kahl BS, Furman RR, et al. Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kd, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). J Clin Oncol. 2013;31(suppl):8526.
-
(2013)
J Clin Oncol
, vol.31
, Issue.SUPPL.
, pp. 8526
-
-
Benson, D.M.1
Kahl, B.S.2
Furman, R.R.3
-
20
-
-
80055021878
-
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: In vivo evidence of immune activation and antitumour response
-
Chanan-Khan AA, Chitta K, Ersing N, et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011; 155(4):457-467.
-
(2011)
Br J Haematol
, vol.155
, Issue.4
, pp. 457-467
-
-
Chanan-Khan, A.A.1
Chitta, K.2
Ersing, N.3
-
21
-
-
4043082729
-
Cuttin edge: Differential roles for phosphoinositide 3-kinases, p110γ and p110δ, lymphocyte chemotaxis and homing
-
Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG. Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol. 2004;173(4): 2236-2240. (Pubitemid 39063077)
-
(2004)
Journal of Immunology
, vol.173
, Issue.4
, pp. 2236-2240
-
-
Reif, K.1
Okkenhaug, K.2
Sasaki, T.3
Penninger, J.M.4
Vanhaesebroeck, B.5
Cyster, J.G.6
-
22
-
-
77951002653
-
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.
-
(2010)
Blood
, vol.115
, Issue.13
, pp. 2578-2585
-
-
Friedberg, J.W.1
Sharman, J.2
Sweetenham, J.3
-
23
-
-
77951450222
-
The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation
-
Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer. 2010;116(9):2201-2207.
-
(2010)
Cancer
, vol.116
, Issue.9
, pp. 2201-2207
-
-
Zent, C.S.1
Laplant, B.R.2
Johnston, P.B.3
-
24
-
-
84871806385
-
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies
-
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies. J Clin Oncol. 2013; 31(1):88-94.
-
(2013)
J Clin Oncol
, vol.31
, Issue.1
, pp. 88-94
-
-
Advani, R.H.1
Buggy, J.J.2
Sharman, J.P.3
-
25
-
-
84879748062
-
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
-
Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
-
(2013)
N Engl J Med
, vol.369
, Issue.1
, pp. 32-42
-
-
Byrd, J.C.1
Furman, R.R.2
Coutre, S.E.3
-
26
-
-
84876477884
-
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling
-
Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood. 2013;121(9): 1501-1509.
-
(2013)
Blood
, vol.121
, Issue.9
, pp. 1501-1509
-
-
Burger, J.A.1
Montserrat, E.2
-
27
-
-
0035871445
-
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
-
Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19(8):2153-2164. (Pubitemid 32366969)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.8
, pp. 2153-2164
-
-
Byrd, J.C.1
Murphy, T.2
Howard, R.S.3
Lucas, M.S.4
Goodrich, A.5
Park, K.6
Pearson, M.7
Waselenko, J.K.8
Ling, G.9
Grever, M.R.10
Grillo-Lopez, A.J.11
Rosenberg, J.12
Kunkel, L.13
Flinn, I.W.14
-
28
-
-
0035469851
-
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
-
Huhn D, von Schilling C, Wilhelm M, et al.; German Chronic Lymphocytic Leukemia Study Group. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98(5): 1326-1331.
-
(2001)
Blood
, vol.98
, Issue.5
, pp. 1326-1331
-
-
Huhn, D.1
Von Schilling, C.2
Wilhelm, M.3
-
29
-
-
0035871441
-
Rituximab dose-escalation trial in chronic lymphocytic leukemia
-
O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19(8): 2165-2170. (Pubitemid 32366970)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.8
, pp. 2165-2170
-
-
O'Brien, S.M.1
Kantarjian, H.2
Thomas, D.A.3
Giles, F.J.4
Freireich, E.J.5
Cortes, J.6
Lerner, S.7
Keating, M.J.8
-
30
-
-
0036757311
-
Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a nordic multicentre study
-
DOI 10.1034/j.1600-0609.2002.02786.x
-
Itälä M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol. 2002; 69(3):129-134. (Pubitemid 35335149)
-
(2002)
European Journal of Haematology
, vol.69
, Issue.3
, pp. 129-134
-
-
Itala, M.1
Geisler, Ch.2
Kimby, E.3
Juvonen, E.4
Tjonnfjord, G.5
Karlsson, K.6
Remes, K.7
-
31
-
-
0037092951
-
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study
-
DOI 10.1182/blood.V99.10.3554
-
Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10): 3554-3561. (Pubitemid 34534522)
-
(2002)
Blood
, vol.99
, Issue.10
, pp. 3554-3561
-
-
Keating, M.J.1
Flinn, I.2
Jain, V.3
Binet, J.-L.4
Hillmen, P.5
Byrd, J.6
Albitar, M.7
Brettman, L.8
Santabarbara, P.9
Wacker, B.10
Rai, K.R.11
-
32
-
-
69849107362
-
Subcutaneous alemtuzumab in fludarabinerefractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the cll2h study of the german chronic lymphocytic leukemia study group
-
Stilgenbauer S, Zenz T, Winkler D, et al.; German Chronic Lymphocytic Leukemia Study Group. Subcutaneous alemtuzumab in fludarabinerefractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009; 27(24):3994-4001.
-
(2009)
J Clin Oncol
, vol.27
, Issue.24
, pp. 3994-4001
-
-
Stilgenbauer, S.1
Zenz, T.2
Winkler, D.3
-
33
-
-
77950502126
-
Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabinerefractory chronic lymphocytic leukemia
-
Wierda WG, Kipps TJ, Mayer J, et al.; Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabinerefractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749-1755.
-
(2010)
J Clin Oncol
, vol.28
, Issue.10
, pp. 1749-1755
-
-
Wierda, W.G.1
Kipps, T.J.2
Mayer, J.3
-
34
-
-
33947243663
-
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
-
DOI 10.1200/JCO.2005.05.0401
-
Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24(34): 5343-5349. (Pubitemid 46623164)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.34
, pp. 5343-5349
-
-
Chanan-Khan, A.1
Miller, K.C.2
Musial, L.3
Lawrence, D.4
Padmanabhan, S.5
Takeshita, K.6
Porter, C.W.7
Goodrich, D.W.8
Bernstein, Z.P.9
Wallace, P.10
Spaner, D.11
Mohr, A.12
Byrne, C.13
Hernandez-Ilizaliturri, F.14
Chrystal, C.15
Starostik, P.16
Czuczman, M.S.17
-
35
-
-
45949100928
-
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
-
Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008; 111(11):5291-5297.
-
(2008)
Blood
, vol.111
, Issue.11
, pp. 5291-5297
-
-
Ferrajoli, A.1
Lee, B.N.2
Schlette, E.J.3
|